| 4-Bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile |
4-溴-6-甲基三唑并[1,5-A]吡啶-3-腈 |
1822680-43-2 |
| 1-cyclopropyl-1H-pyrazol-3-amine |
3-氨基-1-环丙基吡唑 |
1240565-06-3 |
| V-9302 |
V-9302 |
1855871-76-9 |
| methyl 3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoate |
methyl 3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoate |
1239278-73-9 |
| THZ-531 |
THZ531 |
1702809-17-3 |
| 5-azaspiro[2.3]hexane hemioxalate |
5-azaspiro[2.3]hexane hemioxalate |
1638767-88-0 |
| (2R)-5-Oxo-piperidine-2-carboxylic acid hydrochloride |
(2R)-5-氧代哌啶-2-羧酸盐酸盐 |
1427203-51-7 |
| (S)-1-(4-Iodo-5-methoxy-2-nitrophenyl)-2,2-dimethylpropan-1-ol |
(S)-1-(4-碘-5-甲氧基-2-硝基苯基)-2,2-二甲基丙-1-醇 |
1427311-76-9 |
| DBCO-PEG4-SE |
DBCO-PEG4-NHS ESTER |
1427004-19-0 |
| N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine |
AZD9291中间体2 |
1421372-94-2 |
| Mutant EGFR inhibitor |
N-[5-[[5-氯-4-(1H-吲哚-3-基)-2-嘧啶基]氨基]-2-[[2-(二甲基氨基)乙基]甲基氨基]-4-甲氧基苯基]-2-丙烯酰胺 |
1421373-62-7 |
| AZ-5104 |
奥西替尼中间体 |
1421373-98-9 |
| Boc-(S)-3-aMino-2-(hydroxyMethyl)propanoic acid |
BOC-(S)-3-AMINO-2-(HYDROXYMETHYL)PROPANOIC ACID |
1217757-67-9 |
| FMoc-(S)-3-aMino-2-(hydroxyMethyl)propanoic acid |
FMOC-(S)-3-AMINO-2-(HYDROXYMETHYL)PROPANOIC ACID |
1217768-32-5 |
| 6-BroMoisoquinoline-3-carboxylic acid |
6-溴异喹啉-3-甲酸 |
1416713-22-8 |
| 2-(4-Iodo-1H-pyrazol-1-yl)ethanol |
2-(4-碘-1H-吡唑-1-基)乙醇 |
1408334-75-7 |
| 5-BroMo-6-azaindole |
5-溴-1H-吡咯并[2,3-C]吡啶 |
1215387-58-8 |
| 2-Methyl-3-nitro-5-trifluoroMethyl-pyridine |
2-甲基-3-硝基-5-(三氟甲基)吡啶 |
1211537-69-7 |
| 5-fluoro-6-methyl-3-Pyridinamine |
5-fluoro-6-methyl-3-Pyridinamine |
1211542-12-9 |
| 2-broMo-3-Methyl-pyridine-3-carboxyl acid |
2-溴-3-甲基-吡啶-6-羧酸 |
1211516-25-4 |
